Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 6 (2009), Issue 6 (June)

1. Comparison of CT on rails with electronic portal imaging for positioning of prostate cancer patients with implanted fiducial markers.
   Int J Radiat Oncol Biol Phys, 74(3): 906-12. [Abstract] [Full-text]
2. Effect of percentage of positive prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT.
   Urology, 73(6): 1328-34. [Abstract] [Full-text]
3. Population-based analysis of normal Total PSA and percentage of free/Total PSA values: results from screening cohort.
   Urology, 73(6): 1323-7. [Abstract] [Full-text]
4. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.
   Urology, 73(6): 1342-6. [Abstract] [Full-text]
5. Peripheral or axial bone density measurements to identify osteoporosis in prostate cancer patients undergoing androgen deprivation therapy?
   Urology, 73(6): 1347-51. [Abstract] [Full-text]
6. Knockdown of p21-activated kinase 6 inhibits prostate cancer growth and enhances chemosensitivity to docetaxel.
   Urology, 73(6): 1407-11. [Abstract] [Full-text]
7. External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months.
   Int J Radiat Oncol Biol Phys, 74(3): 759-65. [Abstract] [Full-text]
8. Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.
   Eur J Cancer, 45(9): 1664-72. [Abstract] [Full-text]
9. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.
   Int J Radiat Oncol Biol Phys, 74(3): 753-8. [Abstract] [Full-text]
10. Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer.
    Adv Drug Deliv Rev, 61(7): 572-88. [Abstract] [Full-text]
11. Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles.
    Clin Cancer Res, 15(11): 3842-9. [Abstract] [Full-text]
12. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
    Prostate, 69(10): 1128-41. [Abstract] [Full-text]
13. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.
    Prostate, 69(10): 1109-18. [Abstract] [Full-text]
14. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer.
    Prostate, 69(10): 1091-100. [Abstract] [Full-text]
15. Predictors of patient reported outcomes and cost of care in younger men with newly diagnosed prostate cancer.
    Prostate, 69(10): 1067-76. [Abstract] [Full-text]
16. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors.
    Prostate, 69(10): 1034-44. [Abstract] [Full-text]
17. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.
    Prostate, 69(10): 1101-8. [Abstract] [Full-text]
18. Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells.
    Prostate, 69(10): 1077-90. [Abstract] [Full-text]
19. Optimizing molecular signatures for predicting prostate cancer recurrence.
    Prostate, 69(10): 1119-27. [Abstract] [Full-text]
20. Regulation of cell survival by resveratrol involves inhibition of NF kappa B-regulated gene expression in prostate cancer cells.
    Prostate, 69(10): 1045-54. [Abstract] [Full-text]
21. Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor status.
    Prostate, 69(10): 1055-66. [Abstract] [Full-text]
22. Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas.
    Prostate, 69(10): 1025-33. [Abstract] [Full-text]
23. Gene expression of forkhead transcription factors in the normal and diseased human prostate.
    BJU Int, 103(11): 1574-80. [Abstract] [Full-text]
24. Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.
    BJU Int, 103(11): 1472-7. [Abstract] [Full-text]
25. Effect of ageing and body mass index on prostate-specific antigen levels among Chinese men in Singapore from a community-based study.
    BJU Int, 103(11): 1487-91. [Abstract] [Full-text]
26. A 6-year analysis of the clinicopathological profile of patients with prostate cancer at the University Hospital of the West Indies, Jamaica.
    BJU Int, 103(11): 1482-6. [Abstract] [Full-text]
27. Outcome of radical prostatectomy for incidental carcinoma of the prostate.
    BJU Int, 103(11): 1478-81. [Abstract] [Full-text]
28. Plasma phyto-oestrogens and prostate cancer in the European Prospective Investigation into Cancer and Nutrition.
    Br J Cancer, 100(11): 1817-23. [Abstract] [Full-text]
29. A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk.
    Br J Cancer, 100(11): 1799-805. [Abstract] [Full-text]
30. Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer.
    Br J Cancer, 100(11): 1784-93. [Abstract] [Full-text]
31. Neuroendocrine differentiation is involved in chemoresistance induced by EGF in prostate cancer cells.
    Life Sci, 84(25): 882-7. [Abstract] [Full-text]
32. Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts.
    J Steroid Biochem Mol Biol, 115(3): 126-36. [Abstract] [Full-text]
33. Vascular endothelial growth factor receptor 1 expression in pelvic lymph nodes predicts the risk of cancer progression after radical prostatectomy.
    Cancer Sci, 100(6): 1047-50. [Abstract] [Full-text]
34. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.
    Cancer Chemother Pharmacol, 64(3): 445-54. [Abstract] [Full-text]
35. Enhancement of sensitivity and specificity by surface modification of carbon nanotubes in diagnosis of prostate cancer based on carbon nanotube field effect transistors.
    Biosens Bioelectron, 24(11): 3372-8. [Abstract] [Full-text]
36. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.
    J Clin Oncol, 27(17): 2766-71. [Abstract] [Full-text]
37. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
    J Clin Oncol, 27(17): 2772-8. [Abstract] [Full-text]
38. Inhibition of the aquaporin 3 water channel increases the sensitivity of prostate cancer cells to cryotherapy.
    Br J Cancer, 100(12): 1889-95. [Abstract] [Full-text]
39. Suspected malignant cord compression - improving time to diagnosis via a 'hotline': a prospective audit.
    Br J Cancer, 100(12): 1867-72. [Abstract] [Full-text]
40. Identification of betaArrestin2 as a corepressor of androgen receptor signaling in prostate cancer.
    Proc Natl Acad Sci U S A, 106(23): 9379-84. [Abstract] [Full-text]
41. Follow-up care for men with prostate cancer and the role of primary care: a systematic review of international guidelines.
    Br J Cancer, 100(12): 1852-60. [Abstract] [Full-text]
42. C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk.
    Br J Cancer, 100(12): 1846-51. [Abstract] [Full-text]
43. Current management of erectile dysfunction after cancer treatment.
    Curr Opin Oncol, 21(4): 303-9. [Abstract] [Full-text]
44. Duration of androgen suppression in the treatment of prostate cancer.
    N Engl J Med, 360(24): 2516-27. [Abstract] [Full-text]
45. Prostate cancer cognitive-behavioral factors in a West African population.
    J Immigr Minor Health, 11(4): 258-67. [Abstract] [Full-text]
46. Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology.
    Hum Pathol, 40(7): 924-33. [Abstract] [Full-text]
47. Lymphoepithelioma-like carcinoma of the prostate.
    Hum Pathol, 40(7): 982-7. [Abstract] [Full-text]
48. Race/ethnicity and the perception of the risk of developing prostate cancer.
    Am J Prev Med, 37(1): 64-7. [Abstract] [Full-text]
49. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.
    Cancer Res, 69(12): 4937-40. [Abstract] [Full-text]
50. Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2.
    Cancer Res, 69(12): 5202-9. [Abstract] [Full-text]
51. Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis.
    Cancer Res, 69(12): 5007-14. [Abstract] [Full-text]
52. Activation of Rap1 promotes prostate cancer metastasis.
    Cancer Res, 69(12): 4962-8. [Abstract] [Full-text]
53. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer.
    J Natl Cancer Inst, 101(12): 888-92. [Abstract] [Full-text]
54. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.
    J Natl Cancer Inst, 101(12): 878-87. [Abstract] [Full-text]
55. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
    J Clin Oncol, 27(18): 2924-30. [Abstract] [Full-text]
56. Family history of hormonal cancers and colorectal cancer risk: a case-control study conducted in Ontario.
    Int J Cancer, 125(4): 918-25. [Abstract] [Full-text]
57. The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis.
    Int J Cancer, 125(4): 932-41. [Abstract] [Full-text]
58. Physical activity and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.
    Int J Cancer, 125(4): 902-8. [Abstract] [Full-text]
59. CD4+ lymphocytes modulate prostate cancer progression in mice.
    Int J Cancer, 125(4): 868-78. [Abstract] [Full-text]
60. Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells.
    Int J Cancer, 125(4): 774-82. [Abstract] [Full-text]
61. Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer.
    Int J Radiat Oncol Biol Phys, 74(4): 1217-25. [Abstract] [Full-text]
62. Effectiveness of using fewer implanted fiducial markers for prostate target alignment.
    Int J Radiat Oncol Biol Phys, 74(4): 1283-9. [Abstract] [Full-text]
63. Dosimetric effect of prostate motion during helical tomotherapy.
    Int J Radiat Oncol Biol Phys, 74(4): 1134-42. [Abstract] [Full-text]
64. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment.
    Int J Radiat Oncol Biol Phys, 74(4): 1128-33. [Abstract] [Full-text]
65. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity.
    Int J Radiat Oncol Biol Phys, 74(4): 1121-7. [Abstract] [Full-text]
66. Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy.
    Int J Radiat Oncol Biol Phys, 74(4): 1143-9. [Abstract] [Full-text]
67. Fibrils of prostatic acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate cancer.
    J Virol, 83(14): 6995-7003. [Abstract] [Full-text]
68. Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells.
    J Virol, 83(14): 7353-6. [Abstract] [Full-text]
69. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.
    Invest New Drugs, 27(4): 379-86. [Abstract] [Full-text]
70. The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis.
    Eur J Pharmacol, 615(1): 228-33. [Abstract] [Full-text]
71. Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines.
    J Steroid Biochem Mol Biol, 116(1): 29-36. [Abstract] [Full-text]
72. Finding a pathway: information and uncertainty along the prostate cancer patient journey.
    Br J Health Psychol, 14: 437-58. [Abstract] [Full-text]
73. Prostate MR imaging: tissue characterization with pharmacokinetic volume and blood flow parameters and correlation with histologic parameters.
    Radiology, 252(1): 101-8. [Abstract] [Full-text]
74. Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study.
    Cancer, 115(13): 2863-71. [Abstract] [Full-text]
75. Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy.
    Cancer, 115(13): 2872-80. [Abstract] [Full-text]
76. Up-regulation of the inflammatory-reparative phenotype in human prostate carcinoma.
    Prostate, 69(11): 1245-55. [Abstract] [Full-text]
77. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Prostate, 69(11): 1222-34. [Abstract] [Full-text]
78. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
    Prostate, 69(11): 1195-205. [Abstract] [Full-text]
79. Detection of prostate specific transcripts in the peripheral blood during brachytherapy predicts postoperative PSA kinetics.
    Prostate, 69(11): 1235-44. [Abstract] [Full-text]
80. Inhibition of de novo purine synthesis in human prostate cells results in ATP depletion, AMPK activation and induces senescence.
    Prostate, 69(11): 1206-21. [Abstract] [Full-text]
81. Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2.
    Prostate, 69(11): 1188-94. [Abstract] [Full-text]
82. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
    Prostate, 69(11): 1176-87. [Abstract] [Full-text]
83. Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts.
    Prostate, 69(11): 1151-63. [Abstract] [Full-text]
84. Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo.
    Prostate, 69(11): 1143-50. [Abstract] [Full-text]
85. The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: an effect influenced by testosterone.
    Prostate, 69(11): 1164-75. [Abstract] [Full-text]
86. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients.
    J Clin Oncol, 27(19): 3161-8. [Abstract] [Full-text]
87. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.
    J Clin Oncol, 27(19): 3177-84. [Abstract] [Full-text]
88. The effects of a presurgical stress management intervention for men with prostate cancer undergoing radical prostatectomy.
    J Clin Oncol, 27(19): 3169-76. [Abstract] [Full-text]

© 2004-2010 Prostate Cancer Research Today. All Rights Reserved.